---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-033220"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2024-08-20T23:59:59+00:00"
generated_at: "2026-05-31T08:26:43.029765+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma to present at two investor conferences; outlines near-term clinical milestones

## Summary
- Expects to report topline results from influenza A Phase 2a challenge study (CC-42344) in 2024, final report in 2025.
- Expects to report topline results from Phase 1 multiple-ascending cohorts for oral norovirus/coronavirus protease inhibitor CDI-988 in late 2024 or early 2025.
- Management will present at Virtual Investor Summit Microcap Forum on Aug 20, 2024, and H.C. Wainwright Conference starting Sept 9, 2024.

## SEC filing metadata
- accession: 0001493152-24-033220
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2024-08-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315224033220/0001493152-24-033220-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315224033220/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-033220
- JSON: https://secwatch.observer/filing/0001493152-24-033220.json
- Plain text: https://secwatch.observer/filing/0001493152-24-033220.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.